Zepbound Outperforms CagriSema in Head to Head Phase III Obesity Trial Amylin Commands Weight Loss Attention as Industry Anticipates Novo's Phase III CagriSema Readout BioSpace Tirzepatide: a new low for bodyweight and blood glucose The Lancet Diabetes & Endocrinology When semaglutide and tirzepatide stop working for patients, Im adding in cagrilintide. Cagrilintide can add as much as 9% more weight loss to already used GLP1s such as semaglutide, tirzepatide or